AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15936869 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin immediate release (IR) 2.5 mg t.i.d.
Number of subjects: 65
Study 15936869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 2.5 mg t.i.d.
Number of subjects: 65
Study 15936869 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin controlled release (CR) 15 mg q.d.
Number of subjects: 65
Study 15936869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg t.i.d.
Number of subjects: 65
Study 15936869 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin CR 30 mg q.d.
Number of subjects: 65
Study 15936869 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin CR (both doses)
Number of subjects: 65
Study 15936869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (both doses)
Number of subjects: 65
Study 15229420 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation
Number of subjects: 34
Study 15229420 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic epinephrine injection (1:10,000 solution, mean volume 18.0 mL)
Number of subjects: 34
Study 10743448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.15 mg followed by fentanyl 0.05 mg
Number of subjects: 551
Study 10743448 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 15 mg followed by morphine 7 mg
Number of subjects: 551
Study 10743448 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and isoflurane
Number of subjects: 551
Study 10743448 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol
Number of subjects: 551
Study 9384339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc-T
Number of subjects: 75
Study 9384339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc-D
Number of subjects: 75
Study 9384339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9384339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pnc-T and Pnc-D
Number of subjects: 75
Study 8386997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (n = 20)
Number of subjects: 40
Study 8386997 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (n = 20)
Number of subjects: 40
Study 3884411 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil hydrochloride
Number of subjects: 76
Study 3884411 — intervention group
Group type: COMPARATOR
Intervention: Dihydrogenated ergot alkaloids
Number of subjects: 76
Study 3286064 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg i.v.)
Number of subjects: 17
Study 3286064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3286064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal sleep
Number of subjects: 17
Study 3286064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin concentration
Number of subjects: 17
Study 30321319 — intervention group
Group type: EXPERIMENTAL
Intervention: VFR-CV (vacuum‐formed thermoplastic retainers constructed on stone models)
Number of subjects: 30
Study 30321319 — intervention group
Group type: EXPERIMENTAL
Intervention: VFR-3D (vacuum‐formed thermoplastic retainers constructed on 3D printed models)
Number of subjects: 30
Study 30321319 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly defined, but implied as the other intervention in crossover)
Number of subjects: 30
Study 28397155 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit
Number of subjects: 42
Study 26265498 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Number of subjects: 2
Study 23577218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training group (n=34)
Number of subjects: 51
Study 23577218 — intervention group
Group type: COMPARATOR
Intervention: Active control group (n=17)
Number of subjects: 51
Study 21255780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 25
Study 21255780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19151305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anterior approach to sciatic nerve block with 1.5% mepivacaine 20 mL and epinephrine
Number of subjects: 100
Study 19151305 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided posterior (subgluteal) approach to sciatic nerve block with 1.5% mepivacaine 20 mL and epinephrine
Number of subjects: 100
Study 19151305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anterior approach to sciatic nerve block
Number of subjects: 100
Study 19151305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches to sciatic nerve block
Number of subjects: 100
Study 16512755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish administration
Number of subjects: 26
Study 16512755 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 26
Study 15309486 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with 0.02% mitomycin C
Number of subjects: 22
Study 15309486 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with 0.02% mitomycin C
Number of subjects: 22
Study 11545549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 200
Study 11545549 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 200
Study 11545549 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir
Number of subjects: 200
Study 11545549 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir and Ritonavir
Number of subjects: 200
Study 11545549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 200
Study 11545549 — intervention group
Group type: COMPARATOR
Intervention: NRTI-NNRTI
Number of subjects: 200
Study 9311951 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60,000 microg retinol equivalents)
Number of subjects: 3377
Study 9311951 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in xerophthalmic children (n = 86)
Number of subjects: 3377
Study 9311951 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in initially wasted children (n = 34)
Number of subjects: 3377
Study 9311951 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control (300 RE)
Number of subjects: 3377
Study 8365423 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril
Number of subjects: 107
Study 8365423 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 3773023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous solution (IV) only
Number of subjects: 47
Study 3773023 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration along with intravenous solution (ORS/IV)
Number of subjects: 47
Study 3773023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 29575009 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100
Study 29575009 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 26669642 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 144
Study 26669642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 25392971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (2W, 200mJ pulse energy, 10pps)
Number of subjects: 20
Study 25392971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 20
Study 23265585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2502
Study 23265585 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2502
Study 20728874 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 30
Study 20728874 — intervention group
Group type: COMPARATOR
Intervention: Sleep therapy
Number of subjects: 30
Study 18005970 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory sessions and intensive clinical tutorials
Number of subjects: 144
Study 18005970 — intervention group
Group type: COMPARATOR
Intervention: Routine tutoring (control group)
Number of subjects: 144
Study 15717256 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily emtricitabine, didanosine, and efavirenz (n=178)
Number of subjects: 355
Study 15717256 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor (PI) based regimen (n=177)
Number of subjects: 355
Study 15717256 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily emtricitabine, didanosine, and efavirenz
Number of subjects: 355
Study 12860502 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (i.v. 600 mg BID for 7-28 days or switched to oral 600 mg BID)
Number of subjects: 203
Study 12860502 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (i.v. alone or switched to i.m. administration)
Number of subjects: 203
Study 10493326 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated outpatient treatment (IOT)
Number of subjects: 105
Study 10493326 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard alcoholism treatment)
Number of subjects: 105
Study 7563531 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills intervention (5 sessions)
Number of subjects: 128
Study 7563531 — intervention group
Group type: COMPARATOR
Intervention: HIV education condition (1 session)
Number of subjects: 128
Study 7563531 — intervention group
Group type: COMPARATOR
Intervention: Delayed HIV education control (no information until follow-up)
Number of subjects: 128
Study 1836425 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg/4 weeks s.c., n = 20)
Number of subjects: 33
Study 1836425 — intervention group
Group type: COMPARATOR
Intervention: Danazol (2 x 400 mg/day p.o., n = 13)
Number of subjects: 33
Study 7042355 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 300 mg/day
Number of subjects: 147
Study 7042355 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 600 mg/day
Number of subjects: 147
Study 7042355 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg/day
Number of subjects: 147
Study 31680395 — intervention group
Group type: EXPERIMENTAL
Intervention: DLMR01 (polycaprolactone-based dermal filler)
Number of subjects: 30
Study 31680395 — intervention group
Group type: COMPARATOR
Intervention: RJR (purified polynucleotide dermal filler)
Number of subjects: 30
Study 29299741 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling (Group A)
Number of subjects: 43
Study 29299741 — intervention group
Group type: COMPARATOR
Intervention: No ILM peeling (Group B)
Number of subjects: 43
Study 27085886 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP 1 cmH2O
Number of subjects: 72
Study 27085886 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP 10 cmH2O
Number of subjects: 72
Study 27085886 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no PEP)
Number of subjects: 72
Study 27085886 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between PEP 1 cmH2O and PEP 10 cmH2O
Number of subjects: 72
Study 27085886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function and physiological variables
Number of subjects: 72
Study 24684600 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency nurse practitioner service
Number of subjects: 260
Study 24684600 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency department care
Number of subjects: 260
Study 21958930 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-controlled CPR performed by a dedicated medical emergency team using a Philips HeartStart MRx defibrillator.
Number of subjects: 9
Study 20435962 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised care
Number of subjects: 0
Study 20435962 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 17277734 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, 30 minutes, 110% of motor threshold over the right dorso‐lateral prefrontal cortex)
Number of subjects: 15
Study 17277734 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study 15367922 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g alcohol/day
Number of subjects: 53
Study 15367922 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g alcohol/day
Number of subjects: 53
Study 15367922 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol placebo beverage
Number of subjects: 53
Study 12218503 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with bolus intravenous doses of 1 mg morphine for 3 days
Number of subjects: 625
Study 9800817 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene patches
Number of subjects: 52
Study 9800817 — intervention group
Group type: COMPARATOR
Intervention: Polyglycolic acid patches
Number of subjects: 52
Study 7666085 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated MVAC with rhGM‐CSF
Number of subjects: 48
Study 7666085 — intervention group
Group type: COMPARATOR
Intervention: Escalated MVAC alone
Number of subjects: 48
Study 2777422 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of sustained-release urapidil (Ebrantil 60)
Number of subjects: 12
Study 2777422 — intervention group
Group type: COMPARATOR
Intervention: 50 mg urapidil (fast-release tablet)
Number of subjects: 12
Study 30998290 — intervention group
Group type: EXPERIMENTAL
Intervention: ExerciseUP (home-based integrated physical exercise and bladder training with urge suppression and fall prevention program)
Number of subjects: 38
Study 30998290 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study 30998290 — intervention group
Group type: EXPERIMENTAL
Intervention: ExerciseUP
Number of subjects: 38
Study 30998290 — intervention group
Group type: COMPARATOR
Intervention: ExerciseUP and Usual care
Number of subjects: 38
Study 26975647 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 74
Study 26975647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 23934387 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided IA injection
Number of subjects: 60
Study 23934387 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided IA injection
Number of subjects: 60
Study 23934387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both US-guided and palpation-guided IA injections
Number of subjects: 60
Study 22794665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) for 8 weeks
Number of subjects: 29
Study 22794665 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (Control)
Number of subjects: 29
Study 20233509 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 20233509 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 18525393 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exercise
Number of subjects: 8
Study 15673896 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine (30 mg)
Number of subjects: 8
Study 15673896 — intervention group
Group type: COMPARATOR
Intervention: Procaine (80 mg)
Number of subjects: 8
Study 14738262 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.02 mg x kg(-1) followed by thiopentone 3 mg x kg(-1)
Number of subjects: 90
Study 14738262 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone and midazolam co-induction
Number of subjects: 90
Study 14738262 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 9737654 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study 9737654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-channel blockers
Number of subjects: 0
Study 9737654 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic antiarrhythmic therapy
Number of subjects: 0
Study 9737654 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of proarrhythmia and withdrawal of offending agents
Number of subjects: 0
Study 1761344 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid state ambulatory monitoring devices
Number of subjects: 0
Study 1761344 — intervention group
Group type: COMPARATOR
Intervention: Frequency modulated recording device
Number of subjects: 0
Study 6804113 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol, 160 mg once daily for 4 weeks
Number of subjects: 20
Study 6804113 — intervention group
Group type: COMPARATOR
Intervention: Standard propranolol, 40 mg four times daily for 4 weeks
Number of subjects: 20
Study 31222951 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 50 or 70 mg three times weekly (ESA-Naïve group)
Number of subjects: 56
Study 31222951 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 70 or 100 mg three times weekly (ESA-Converted group)
Number of subjects: 56
Study 31222951 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (both groups)
Number of subjects: 56
Study 31222951 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (ESA-Naïve group)
Number of subjects: 56
Study 31222951 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (ESA-Converted group)
Number of subjects: 56
Study 31222951 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 56
Study 30299415 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep drain
Number of subjects: 100
Study 30299415 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 100
Study 28744099 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (40 mg, single dose)
Number of subjects: 81
Study 28744099 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (10 mg, multiple dose)
Number of subjects: 81
Study 28744099 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (≥2 mg)
Number of subjects: 81
Study 28744099 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (single and multiple doses)
Number of subjects: 81
Study 28744099 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (fasted and fed states)
Number of subjects: 81
Study 28744099 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (multiple daily doses)
Number of subjects: 81
Study 28744099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 27046160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 or 60 mg twice daily)
Number of subjects: 6806
Study 27046160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6806
Study 24442532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup feeding
Number of subjects: 522
Study 24442532 — intervention group
Group type: COMPARATOR
Intervention: Bottle feeding
Number of subjects: 522
Study 24442532 — intervention group
Group type: COMPARATOR
Intervention: Cup feeding and Bottle feeding
Number of subjects: 522
Study 22585772 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiretrovirals (ARVs) during pregnancy, labor, and postpartum
Number of subjects: 236
Study 19938709 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic colloid solutions
Number of subjects: 0
Study 19938709 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17674759 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Postoperative management at one week after operation, then weekly for the first and second month, bi-weekly for the third and fourth month, and monthly after the fifth month.
Number of subjects: 80
Study 17674759 — intervention group
Group type: COMPARATOR
Intervention: Group B: Postoperative management at two weeks after operation, then bi-weekly for the first and second month, monthly from third to fifth month, and bi-monthly after sixth month.
Number of subjects: 80
Study 17674759 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Rate of epithelialization measured at third month.
Number of subjects: 80
Study 17674759 — intervention group
Group type: COMPARATOR
Intervention: Group B: Rate of epithelialization measured at third month.
Number of subjects: 80
Study 17674759 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Efficiency rate measured at twelfth month.
Number of subjects: 80
Study 17674759 — intervention group
Group type: COMPARATOR
Intervention: Group B: Efficiency rate measured at twelfth month.
Number of subjects: 80
Study 15206017 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg procaine hydrochloride
Number of subjects: 0
Study 15206017 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 0
Study 11199949 — intervention group
Group type: EXPERIMENTAL
Intervention: Opipramol (200 mg/day)
Number of subjects: 307
Study 11199949 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (2 mg/day)
Number of subjects: 307
Study 11199949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 9472839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/24 hr for 8 weeks
Number of subjects: 25
Study 9472839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7594335 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg once daily
Number of subjects: 24
Study 7594335 — intervention group
Group type: COMPARATOR
Intervention: famotidine 20 mg twice daily
Number of subjects: 24
Study 2174652 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml 0.75% prilocaine hydrochloride with 5 ml 8.4% sodium bicarbonate
Number of subjects: 80
Study 2174652 — intervention group
Group type: COMPARATOR
Intervention: 5 ml 0.9% saline
Number of subjects: 80
Study 6986111 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive instrument used in emergency room during experimental months (401 patients)
Number of subjects: 856
Study 6986111 — intervention group
Group type: COMPARATOR
Intervention: Control months (455 patients)
Number of subjects: 856
Study 31935834 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated downward referral
Number of subjects: 1198
Study 31935834 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's advice
Number of subjects: 1198
Study 31935834 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing willingness for downward referral
Number of subjects: 1198